A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor

Summary

This study is an open-label, multicenter, dose-escalation and dose-expansion Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of AK150 in patients with advanced malignant solid tumors.

Timeline

Start

2026-04-30

Primary completion

2029-02-21

Completion

2029-06-07

Drugs

Indications